Biopharmaceutical company UCB (Euronext Brussels:UCB) and Domino Data Lab, a data science platform provider, announced on Monday a strategic collaboration aimed at modernising a Statistical Computing Environment (SCE) for the life sciences industry.
The partnership aims to convert legacy SCE into unified, scalable and flexible platforms to meet the evolving demands of clinical research, regulatory compliance and efficient data analysis.
UCB and Domino Data Lab plan to implement a modern cloud-enabled environment that integrates diverse analytical tools, such as SAS, R and Python, within a unified framework, using Domino's expertise in cloud technologies and open-source support combined with UCB's clinical research and regulatory expertise.
This is intended to enhance research capabilities and maintain compliance with industry standards like GxP, FDA 21 CFR Part 11 and GDPR.
CARsgen's Satri-cel granted Chinese Priority Review
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
FDA approves Bio-Thera and Hikma's biosimilar STARJEMZA for US market
Innate Pharma reports sustained efficacy of lacutamab in Sézary syndrome and mycosis fungoides
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Life Molecular Imaging and SOFIE announce Neuraceq distribution in Albany, NY
UCB and Domino Data Lab partner to modernise Statistical Computing Environment for life sciences